Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus type 1 infection in immunosuppressed mice.
1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) reduced the mortality rates of (i) 7-week-old, cyclophosphamide-treated, immunosuppressed mice (CYP mice) intraperitoneally infected with a moderately virulent strain of herpes simplex virus type 1 and (ii) 4-week-old CYP mice infected with a less virulent strain at doses of 20 and 50 mg/kg of body weight twice daily and 5 mg/kg, respectively. The degree of efficacy of BV-araU was equivalent to that of acyclovir in 4-week-old CYP mice infected with the less virulent strain. BV-araU (20 mg/kg) suppressed viral growth in various organs of CYP mice.
Ijichi
K
K
Research and Development Division, Yamasa Shoyu Co., Ltd., Choshi, Japan.
Ashida
N
N
Machida
H
H
D000212:Acyclovir / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D006561:Herpes Simplex / Q000188:drug therapy* / Q000382:microbiology; D007165:Immunosuppression Therapy; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D018139:Simplexvirus; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; D003520:Cyclophosphamide; C031368:sorivudine; D000212:Acyclovir